Hidden heart risks in testicular cancer survivors: a closer look at chemotherapy's long shadow
NCT ID NCT05611307
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This study investigates whether testicular cancer survivors who received cisplatin-based chemotherapy and bone marrow transplant have hidden heart disease that standard checkups might miss. Researchers will use advanced blood tests and CT scans to measure cholesterol, plaque in the arteries, and hormone levels. The goal is to understand how past cancer treatments may affect heart health years later.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If this study finds clear signs of early heart disease, it could lead to better screening and preventive care for testicular cancer survivors.
- What could go wrong
- This is an observational study, not a treatment trial, so it will not test any new therapy. The findings may not apply to all survivors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASCVD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Indiana University
RECRUITINGIndianapolis, Indiana, 46202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan replace invasive heart imaging before bypass surgery?
- Epilepsy drug may protect organs during heart surgery — trial tests the idea
- A simple eye mask might protect sleep and calm confusion after heart surgery
- Software-Guided heart procedures: a new standard for coronary care?
- Heart patients may stay active longer with coach calls and group support
- Sitting less could be a lifeline for frail hearts – a new trial tests a simple program